These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 4730978)

  • 1. [Early results of sputum-positive patients with newly-detected pulmonary tuberculosis with rifampicin combined with isoniazid and SM (preliminary report)].
    Ropek M; Szymański A; Banaszkiewicz H; Chetkowski A; Czaplińska-Jóźwiak E; Dabrowska-Solecka Z; Ignaczak J; Kondratowicz W; Królikowska H; Pawlik J; Pawlowska I; Sliwińska M; Szuster I; Szymánska W
    Gruzlica; 1973 Jul; 41(7):777-80. PubMed ID: 4730978
    [No Abstract]   [Full Text] [Related]  

  • 2. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
    Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC;
    Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of rifampicin in the treatment of pulmonary tuberculosis. Results at 12 months.
    Sriyabhaya N; Jarumilin A
    J Med Assoc Thai; 1972 Apr; 55(4):235-7. PubMed ID: 5022496
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of pleural and pulmonary tuberculosis by drug combinations including rifampicin. Early results].
    Cornudella R; Garcia-Besada JA; Castellano A
    Rev Clin Esp; 1972 Jul; 126(1):59-64. PubMed ID: 5080189
    [No Abstract]   [Full Text] [Related]  

  • 6. [Reduction of fresh forms of pulmonary tuberculosis by the classical treatment and by combined antibiotics including rifampicin (comparative study of a personal survey)].
    Weill G; Lévy A; Guignon JP; Lecoq H; Friess JM; Maman P
    Rev Tuberc Pneumol (Paris); 1969 Dec; 33(8):1119-25. PubMed ID: 4916253
    [No Abstract]   [Full Text] [Related]  

  • 7. Modified short-course chemotherapy of pulmonary tuberculosis in Ibadan, Nigeria--a preliminary report.
    Ige OM; Bakare NA; Onadeko BO
    Afr J Med Med Sci; 2000 Mar; 29(1):51-3. PubMed ID: 11379469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Maximum therapeutic efficiency of a guternary antitubercular preparation. (Streptomycin-ethambutol-rifampicin-isoniazid)].
    Almansa de Cara S
    Rev Clin Esp; 1972 May; 125(4):353-6. PubMed ID: 5080180
    [No Abstract]   [Full Text] [Related]  

  • 9. Short-course treatment in pulmonary tuberculosis.
    East Afr Med J; 1973 Dec; 50(12):672-80. PubMed ID: 4132127
    [No Abstract]   [Full Text] [Related]  

  • 10. [Late results of treatment of chronic pulmonary tuberculosis with rifampicin].
    Lachowicz E; Polaczek E; Araszkiewicz W; Kozakow H; Pszonicka A; Styszewska H; Janowiec M; Grabowska R
    Gruzlica; 1973 Jul; 41(7):781-7. PubMed ID: 4730979
    [No Abstract]   [Full Text] [Related]  

  • 11. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.
    Chan SL; Yew WW; Ma WK; Girling DJ; Aber VR; Felmingham D; Allen BW; Mitchison DA
    Tuber Lung Dis; 1992 Feb; 73(1):33-8. PubMed ID: 1326348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and outcome of tuberculosis patients whose sputum smears are positive at or after 5 months of treatment.
    Harries AD; Gausi F; Chimzizi R; Salaniponi FM
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):384-7. PubMed ID: 15139479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures.
    Tam CM; Chan SL; Kam KM; Goodall RL; Mitchison DA
    Int J Tuberc Lung Dis; 2002 Jan; 6(1):3-10. PubMed ID: 11931398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug resistance to the first line of antitubercular regimen (a preliminary report).
    Varaiya A; Gogate A
    Indian J Public Health; 1998; 42(4):126-30. PubMed ID: 10389525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Short-term treatment of pulmonary tuberculosis].
    Karuga WK
    Bull Int Union Tuberc; 1974; 49(1):388-97. PubMed ID: 4143178
    [No Abstract]   [Full Text] [Related]  

  • 16. Yield of continued monthly sputum evaluation among tuberculosis patients after culture conversion.
    Sundaram V; Fujiwara PI; Driver CR; Osahan SS; Munsiff SS
    Int J Tuberc Lung Dis; 2002 Mar; 6(3):238-45. PubMed ID: 11934142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients].
    Khodashova ML; Iuditskiĭ MV; Semenova OV
    Probl Tuberk Bolezn Legk; 2004; (3):26-8. PubMed ID: 15338896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of initial drug resistance to M. tuberculosis in new sputum positive RNTCP patients.
    Dhingra VK; Rajpal S; Bhalla P; Yadav A; Jain SK; Hanif M
    J Commun Dis; 2003 Jun; 35(2):82-9. PubMed ID: 15562953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative controlled trial of rimactane in pulmonary tuberculosis.
    Dormer BA
    Int Z Klin Pharmakol Ther Toxikol; 1969 Apr; 2(2):188. PubMed ID: 4895449
    [No Abstract]   [Full Text] [Related]  

  • 20. [Late results of treatment with rifampicin combined with SM and INH in newly detected cases of pulmonary tuberculosis].
    Szymański A
    Pneumonol Pol; 1976 Mar; 44(3):227-35. PubMed ID: 1257096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.